Analysts Set United Therapeutics Co. (NASDAQ:UTHR) PT at $370.86

Shares of United Therapeutics Co. (NASDAQ:UTHR) have earned an average recommendation of “Moderate Buy” from the fifteen analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $370.86.

Several brokerages have weighed in on UTHR. TD Cowen boosted their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Argus upped their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH raised their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. HC Wainwright boosted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, Jefferies Financial Group increased their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a report on Monday, September 23rd.

United Therapeutics Stock Performance

UTHR stock opened at $356.33 on Monday. The firm has a market cap of $15.91 billion, a P/E ratio of 15.65, a P/E/G ratio of 1.05 and a beta of 0.57. The firm’s fifty day moving average is $370.42 and its 200 day moving average is $351.01. United Therapeutics has a 52 week low of $208.62 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. During the same period last year, the firm earned $5.38 earnings per share. The company’s revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, analysts forecast that United Therapeutics will post 25.22 EPS for the current year.

Insider Activity

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the transaction, the director now owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Judy D. Olian sold 1,750 shares of United Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the transaction, the director now owns 5,655 shares of the company’s stock, valued at $2,332,574.40. The trade was a 23.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 142,422 shares of company stock worth $53,498,732 in the last quarter. 11.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ClariVest Asset Management LLC grew its stake in shares of United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares during the last quarter. USA Financial Formulas bought a new position in United Therapeutics in the 3rd quarter worth about $33,000. Brooklyn Investment Group purchased a new stake in United Therapeutics during the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP bought a new stake in United Therapeutics during the 3rd quarter valued at about $82,000. Finally, Values First Advisors Inc. purchased a new position in United Therapeutics in the third quarter worth about $90,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.